Power morcellator for uterine fibroid removal not linked to cancer risk
the ONA take:
According to new findings published in the journal JAMA Oncology, researchers have found that the risk of bits of hidden cancerous tumors spreading throughout the abdomen when a power morcellator is used to remove fibroids in the uterus is low.
Before the U.S. Food and Drug Administration issued a black-box warning on the devices last November that the morcellator could spread and worsen an undetected cancerous uterine tumor, power morcellators were commonly used during minimally invasive surgery to remove uterine fibroids.
Uterine fibroids, which are non-cancerous growths in the uterine wall, are very common, but sometimes need to be removed when they cause pelvic pain and heavy menstrual bleeding. Treatment options include a hysterectomy to remove the uterus or surgery to remove the fibroids.
For the study, researchers identified 42,000 American women who had fibroids removed between 2006 and 2012, 3,200 of which were removed with power morcellators.
Of those, three were found to have uterine cancer, meaning the odds of developing uterine cancer after uterine fibroid removal was about 1 in 1,000 patients compared with 1 in 528 among women whose fibroid removal did not involve the power morcellators. The researchers note that the findings are reassuring.
Risk of bits of hidden cancerous tumors spreading throughout the abdomen when a power morecellator is used to remove fibroids in the uterus is low.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|